Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

Sanofi is playing catch-up in gene therapy, but new CEO Paul Hudson is taking quick steps to close the gap. A reorganization of the R&D unit is intended to pivot the drugmaker toward immuno-oncology drugs and gene therapies. And to hasten the transition, the company is retrofitting a vaccine plant in France into a gene therapy manufacturing operation. (source:

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Leave a Reply

Your email address will not be published. Required fields are marked *